ecrin-mdr-crcClinical2013Prostatic NeoplasmsMetastatic Breast CancerColorectal CancerProstate CancerProstatic NeoplasmsMetastatic Breast CancerColorectal CancerProstate CancerInterventionalhttps://newmdr.ecrin.org/Study/2157558Denmark6Wnt-5AFoxy-5ECRIN MDRCompletedfalsePhase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate CancerThe Wnt proteins belong to a family of proteins that have been demonstrated to play a role in the formation and dissemination of tumours. The present project focuses on the critical role of the Wnt-5a protein in the pathobiological processes that lead to metastatic cancer disease. WntResearch has identified a formylated 6 amino acid peptide fragment, named Foxy-5, which mimick the effects of Wnt-5a to impair migration of epithelial cancer cells and thereby acting anti-metastatic. The aim of the present clinical phase 1 trial is to establish the recommended dose for a clinical phase 2 study and thereby further develop Foxy-5 as a first in class anti-metastatic cancer drug. Foxy-5 is designed to inhibit the development of metastasis by reducing the motility of cancer cells and should thereby increase the survival rates of patients with solid malignant tumours.2013-06-152157558NCT02020291